Losartan Potassium
Product Images NDC 67296-2057

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67296-2057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25 mg,90 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

This text appears to be a label or information related to a medication called Losartan Potassium Tablets, USP. It provides details such as the manufacturer (Fong i Pramasescal Co.), recommended storage conditions (controlled room temperature), quantity (90 tablets), and doses (25 mg). There are also references to NDC codes and distributor details. Additionally, the text mentions that the tablets should be kept in the original container and that the box is designed to dispense with ease.*

FDA Label Image

50 mg 30 Tablets (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07)

FDA Label Image

100 mg 30 Tablets (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08)

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This text provides a comparison between Atenolol and Losartan Potassium in terms of their effectiveness in reducing the primary endpoint in patients. The study shows an adjusted risk reduction of 13% with a statistically significant p-value of 0.021 over a 66-month period.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This text provides information on a medication switch from Atenolol to Losartan Potassium with an adjusted risk reduction of 25% and a p-value of 0.001. It also presents the percentage of patients with fatal/non-fatal stroke at different study months, ranging from 6 to 66.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

This is a table showing the primary endpoint events within different demographic subgroups in a study comparing Losartan and Atenolol for stroke prevention. The table includes data on event rates, hazard ratios, and subgroup breakdowns based on age, gender, race, history of cardiovascular disease, diabetes, and isolated systolic hypertension. These results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. The sample includes a diverse range of racial backgrounds such as Black, White, Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, and European.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This text shows the comparison of patients with an event between those taking Losartan Potassium and Placebo over a 48-month period. The data indicates a risk reduction of 16.1% in patients taking Losartan Potassium compared to Placebo, with a statistical significance of p=0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.